{"id":578,"date":"2015-06-17T15:57:08","date_gmt":"2015-06-17T10:27:08","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=578"},"modified":"2025-05-05T17:28:22","modified_gmt":"2025-05-05T11:58:22","slug":"chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","title":{"rendered":"Chimeric Antigen Receptor T-cell Therapy Landscape"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fea8f379151\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fea8f379151\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#What_is_CAR-T_Cell_Therapy\" >What is CAR-T Cell Therapy?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#CAR-T_Therapy_Landscape\" >CAR-T Therapy Landscape<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#Technology\" >Technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#Attractive_Pipeline\" >Attractive Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#Partnerships\" >Partnerships<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#Indications\" >Indications<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#CAR-T_Cells_Therapy_Info-graph\" >CAR-T Cells Therapy Info-graph<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#DelveInsight_Expert_Comments\" >DelveInsight Expert Comments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\/#Upcoming_DelveInsight_Report_on_CAR-T_Cell_Therapies-Landscape_2015\" >Upcoming DelveInsight Report on CAR-T Cell Therapies-Landscape, 2015<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<blockquote>\n<p>In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy <img decoding=\"async\" class=\" size-medium wp-image-584 alignright\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300\" alt=\"CAR-T\" width=\"300\" height=\"225\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/car-t.jpg 800w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/car-t-300x225.jpg 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/car-t-768x576.jpg 768w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. <strong><span style=\"color: #993366;\">There are 35+ products in pipeline and 40+ companies are active in this field.<\/span><\/strong><\/p>\n<p><strong>With the advancement of (CAR) T-cell technology showing more safety and efficacy, the companies dealing with immunotherapy are grabbing the opportunity to enter in this new emerging market by the routes of collaborations and acquisitions.<\/strong><\/p>\n<\/blockquote>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_CAR-T_Cell_Therapy\"><\/span>What is CAR-T Cell Therapy?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.<\/strong> CARs are specifically designed receptors, which graft specificity into an&nbsp;immune effector cell. This therapy acts as genetic modification of T-cells from cancer patients by gene transfer of chimeric antigen receptors (CARs) to recognize molecules on cancer cells without relying on MHC presentation. This adoptive T-cell therapy harnesses the power of the immune system to target and kill tumor cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_Therapy_Landscape\"><\/span>CAR-T Therapy Landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technology\"><\/span>Technology<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Most of the companies are dealing with the conventional <strong>CAR T-cell technology<\/strong>,<strong> targeting CD19 antigen of lymphoma cells, which is occupying more than 50% share in target antigens<\/strong>. Meanwhile, the companies are also investing on the studies targeting <strong>25+ different antigens<\/strong> of cancer cells as well as the firms are coming up with<strong> 8+ different technologies<\/strong> to enhance the safety and efficacy of the CAR T-cell therapy.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Attractive_Pipeline\"><\/span>Attractive Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>There are <strong>35+ pipeline products and 40+ companies\u2019<\/strong> including small and big firms are actively involved. Out of 40 companies, 15+ leading companies are involved with their product in clinical phases. <strong>Novartis with the Phase-II product CTL019 is leading the race.<\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Partnerships\"><\/span>Partnerships<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>With <strong>25+ collaborations<\/strong> happened in recent years, Juno Therapeutics (JUNO) has inked a massive $727 million R&amp;D deal with Editas Medicine that is considered as greatest deal in this segment. <strong>7+ Research institutes and 12+ small firms<\/strong> having core CAR T-cell technologies partnered with some of the leading companies for the development of CAR-T cell therapy.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Indications\"><\/span>Indications<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>As CAR-T technology are showing most promising results in cancer studies, companies are conducting their Pre-clinical and clinical trial studies with <strong>18+ Oncology indications<\/strong>, in which B-cell malignancies, Lymphoma &amp; Leukemia are the prominent one.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CAR-T_Cells_Therapy_Info-graph\"><\/span>CAR-T Cells Therapy Info-graph<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter\"><img decoding=\"async\" width=\"445\" height=\"419\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t-therapy.png?w=300\" alt=\"CAR-T Therapy\" class=\"wp-image-582\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/car-t-therapy.png 445w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/06\/car-t-therapy-300x282.png 300w\" sizes=\"(max-width: 445px) 100vw, 445px\" \/><\/figure><\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"DelveInsight_Expert_Comments\"><\/span>DelveInsight Expert Comments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>CAR T-cell therapy will drive the future of Immunotherapy to promising heights. The companies with lagging attention to this approach are already behind. The deals will continue to increase the market size and continued desperation to get on surviving with the key risks on this competitive landscape, numerous players could end up basking in reflected glory.<\/p>\n\n\n\n<p><em>Written by Vikas Soni, Trainee at DelveInsight<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Upcoming_DelveInsight_Report_on_CAR-T_Cell_Therapies-Landscape_2015\"><\/span>Upcoming DelveInsight Report on CAR-T Cell Therapies-Landscape, 2015<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>For more information on this Report, mail us at <a href=\"mailto:info@delveinsight.com\">info@delveinsight.com<\/a><\/p>\n\n\n\n<p><strong><em>Let&#8217;s share our knowledge, provide your comments in the&nbsp;comment section<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and 40+ companies are active in this field. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[141,150,162,168,173,315,423,427,451,477,491],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-578","post","type-post","status-publish","format-standard","hentry","category-articles","tag-car-t-therapy-landscape","tag-cd19-antigen","tag-chimeric-antigen-receptor-car-t-cell-therapy","tag-clinical-trial","tag-collaborations","tag-immunotherapy","tag-novartis","tag-oncology","tag-partnerships","tag-pipeline","tag-pre-clinical","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Chimeric Antigen Receptor T-Cell Therapy Market Landscape<\/title>\n<meta name=\"description\" content=\"CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chimeric Antigen Receptor T-Cell Therapy Market Landscape\" \/>\n<meta property=\"og:description\" content=\"CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-06-17T10:27:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:58:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chimeric Antigen Receptor T-Cell Therapy Market Landscape","description":"CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","og_locale":"en_US","og_type":"article","og_title":"Chimeric Antigen Receptor T-Cell Therapy Market Landscape","og_description":"CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.","og_url":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-06-17T10:27:08+00:00","article_modified_time":"2025-05-05T11:58:22+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","url":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report","name":"Chimeric Antigen Receptor T-Cell Therapy Market Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300","datePublished":"2015-06-17T10:27:08+00:00","dateModified":"2025-05-05T11:58:22+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"CAR T-cells are the engineered T-cells to express chimeric antigen receptor (CARs) which identifies specific antigens of a target-cell.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chimeric-antigen-receptor-car-t-cell-therapy-landscape-a-report#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/06\/car-t.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR-T Therapy Landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CD19 antigen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chimeric Antigen Receptor (CAR) T-cell Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">clinical trial<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immunotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Partnerships<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pre-clinical<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR-T Therapy Landscape<\/span>","<span class=\"advgb-post-tax-term\">CD19 antigen<\/span>","<span class=\"advgb-post-tax-term\">Chimeric Antigen Receptor (CAR) T-cell Therapy<\/span>","<span class=\"advgb-post-tax-term\">clinical trial<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Immunotherapy<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Partnerships<\/span>","<span class=\"advgb-post-tax-term\">Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pre-clinical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jun 17, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Jun 17, 2015 3:57 pm","modified":"Updated on May 5, 2025 5:28 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=578"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/578\/revisions"}],"predecessor-version":[{"id":31672,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/578\/revisions\/31672"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=578"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=578"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}